COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
30/06/2026
Key U.S. patent now protects exclusivity for developing stenoparib with the stenoparib-DRP ® until April 2042 TARPON SPRINGS, Fla., June 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR [...]
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
30/06/2026
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity [...]
R1 Therapeutics establishes world-class Scientific Advisory Board to support advancement of AP306 in Chronic Kidney Disease
30/06/2026
Seven internationally recognized nephrology experts join R1's Scientific Advisory Board Strengthens scientific and clinical guidance as AP306 advances into global Phase 2b development for the treatment of [...]
iKrusher Invests in Canadian Operations to Improve Supply Chain Reliability and Speed to Market for Vape Brands
30/06/2026
Established vape technology company helps Canadian cannabis brands navigate operational pressures and deliver more dependable product experiences Mississauga, Ontario, June 30, 2026 (GLOBE NEWSWIRE) -- Canadian cannabis [...]
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
30/06/2026
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “ [...]
Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer
30/06/2026
- Proceeds will fund advancement of AR ON degrader, FX-111, to proof of concept and preclinical development of AR ON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through [...]
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
30/06/2026
Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent [...]
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
30/06/2026
InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient development plan to [...]
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
30/06/2026
Brings more than 25 years of experience advancing and commercializing high-impact therapies for serious diseases, including those with limited or no approved treatment options Extensive public company and rare disease [...]
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
30/06/2026
Plus Therapeutics to become Cerenome, to trade under new Nasdaq ticker CNSY on August 3, 2026 Affirms 2026 guidance on key milestones Reports positive CNSide ® commercial progress HOUSTON, June 30, 2026 (GLOBE NEWSWIRE [...]
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
30/06/2026
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for [...]
Commure Launches Orchestrator: The AI-Native Referral Management and Patient Intake Platform
30/06/2026
The solution closes the gap between referral sent and patient seen – eliminating fax-based workflows, reducing referral leakage, and cutting pre-visit administrative burden MOUNTAIN VIEW, Calif. , June 30, 2026 (GLOBE [...]
MediciNova CEO Provides Shareholder Update
30/06/2026
LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients
30/06/2026
FocalTherics™ Announces Successful Launch of First Commercial Endometriosis Focal One® Program in Europe with Treatment of Initial Patients AUSTIN, Texas, June 30, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) ( [...]
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
30/06/2026
Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated safety profile for [...]
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
30/06/2026
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of [...]
Weight Watchers Med+ Establishes Access to GLP-1s Through Medicare GLP-1 Bridge Program
30/06/2026
Weight Watchers expands access for Med+ Medicare beneficiaries to GLP-1 medications covered by the Medicare Bridge Program. NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight [...]
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
30/06/2026
New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic license. KNOXVILLE, Tenn [...]
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
30/06/2026
Data Demonstrate Vamorolone’s Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses CORAL GABLES, Fla., June 30, 2026 ( [...]

Pages